Identification of biomarkers in pazopanib treated patients with renal cell carcinoma

Amy M Pick, Zara Risoldi Cochrane


Targeted therapy has become the mainstay in the treatment of renal cell carcinoma (RCC). That being said, it is difficult to predict which patients will respond to targeted therapy. A recent article published in The Lancet Oncology attempts to identify biomarkers in patients receiving pazopanib that may be helpful in the clinical management of renal cell carcinoma.